English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since a long line of years we have studied liver growth regulation (cell proliferation, apoptosis) in vivo. One of the prominent findings was that TGF-β1 constitutes a major death signal in rat liver, acting in concert with nutritional factors to maintain liver cell number homeostasis. Toxicological tests with rodents in vivo showed that liver tumor promoter (e.g. phenobarbital) favour cell multiplication and inhibit apoptosis, thereby accelerating hepatocarcinogenesis. To elucidate their mode of action (MOA), along with the general need for alternative test models in toxicology, we searched for a liver cell culture system yielding a high concordance with our in vivo findings. Here we report on a newly established cell line HCC-1.2 [Grasl-Kraupp et al., submitted] exhibiting the following features: (1) a high sensitivity towards the anti-proliferative and pro-apoptotic action of TGF-β1; (2) apoptosis is mediated via the intrinsic pathway as demonstrated by caspase analysis; (3) inhibition of TGF-β1-induced apoptosis by liver tumor promoter, as exemplified by phenobarbital; (4) glucose withdrawal exerts an additive effect to the pro-apoptotic action of TGF-β1, all of which agree with our previous in vivo observations on liver growth regulation. Thus, our observations suggest that the HCC1.2 cells constitute a valid test system as it meets well with prerequists for further studies tackling the MOA of liver tumor promoter, along with their interaction with nutritional factors. from 13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT) Vienna, Austria. 22–24 November 2007

bmc pharmacology

Control of hepatocellular apoptosis by cytokines (TGF-β1), liver tumor promoter (phenobarbital) and nutritional factors (glucose): approach to validate the hepatoma cell line HCC-1.2 as cell culture model